High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer by Ghadjar, Pirus et al.
High-Dose (80 Gy) Intensity-Modulated Radiation 
Therapy with Daily Image-Guidance as Primary Treat-
ment for Localized Prostate Cancer
Pirus Ghadjar, Nicole Gwerder, Peter Manser, Jacqueline Vock, Axel Madlung, Roberto Mini, 
Daniel M. Aebersold1
Original Article
Strahlentherapie 
und Onkologie
1Department of Radiation Oncology with Division of Medical Radiation Physics, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Received: May 25, 2010; accepted: September 16, 2010
Published Online: November 30, 2010
687Strahlenther Onkol 2010 · No. 12  © Urban & Vogel
Purpose: To report acute and late toxicity in prostate cancer patients treated by high-dose intensity-modulated radiation 
therapy (IMRT) with daily image-guidance.
Patients and Methods: From 06/2004–03/2008, 102 men were treated with 80 Gy IMRT with daily image-guidance. The risk 
groups were as follows: low, intermediate, and high risk in 21%, 27%, and 52% of patients, respectively. Hormone therapy was 
given to 65% of patients. Toxicity was scored according to the CTC scale version 3.0.
Results: Median age was 69 years and median follow-up was 39 months (range, 16–61 months). Acute and late grade 2 gas-
trointestinal (GI) toxicity occurred in 2% and 5% of patients, respectively, while acute and late grade 3 GI toxicity was absent. 
Grade 2 and 3 pretreatment genitourinary (GU) morbidity (PGUM) were 15% and 2%, respectively. Acute grade 2 and 3 GU toxic-
ity were 43% and 5% and late grade 2 and 3 GU toxicity were 21% and 1%, respectively. After multiple Cox regression analysis, 
PGUM was an independent predictor of decreased late ≥ grade 2 GU toxicity-free survival (hazard ratio = 9.4 (95% confidence 
interval: 4.1, 22.0), p < 0.001). At the end of follow-up, the incidence of late grade 2 and 3 GU toxicity decreased to 7% and 
1%, respectively.
Conclusion: GI toxicity rates after IMRT with daily image-guidance were excellent. GU toxicity rates were acceptable and 
strongly related to PGUM.
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Intensitätsmodulierte Hochdosis-Radiotherapie (80 Gy) mit täglicher Image Guidance als Primärtherapie beim 
 lokalisierten Prostatakarzinom
Ziel: Beschreibung der Akut- und Spätnebenwirkungen bei Patienten mit Prostatakarzinom, die mit intensitätsmodulierter Hoch-
dosis-Radiotherapie (IMRT) und täglicher Image Guidance behandelt wurden.
Patienten und Methodik: Von 06/2004 bis 03/2008 wurden 102 Männer mit 80 Gy IMRT behandelt. Die Zuordnung zu Risi-
kogruppen ergab: niedrig bei 21%, mittelhoch bei 27% und hoch bei 52% der Patienten. Hormontherapie erhielten 65% der 
Patienten. Die Toxizität wurde anhand der CTC Kriterien Version 3.0 bestimmt.
Ergebnisse: Das mediane Alter betrug 69 Jahre und die mediane Nachbeobachtungszeit war 39 Monate (Spannbreite, 16–61 
Monate). Akute und späte Grad-2-gastrointestinale (GI) Nebenwirkungen traten in 2% und 5% der Fälle auf; akute oder späte 
Grad-3-GI Nebenwirkungen wurden nicht beobachtet. Die Grad-2- und -3-urogenitale (GU) Morbidität, welche bereits vor IMRT 
bestand (PGUM), betrug 15% und 2%. Akute Grad-2- und -3-GU Nebenwirkungen lagen bei 43% und 5% und späte Grad-2- und 
-3-GU Nebenwirkungen bei 21% und 1%. In der multiplen Cox Regressionsanalyse erwies sich PGUM als unabhängiger Prädiktor 
für ein verkürztes (spät) ≥Grad-2-GU nebenwirkungsfreies Überleben (hazard ratio = 9.4 [95% confidence interval: 4.1, 22.0], 
p < 0.001). Am Ende des Nachbeobachtungszeitraumes sank die Inzidenz von späten Grad-2 und -3-GU Nebenwirkungen auf 7% 
und 1%.
Schlussfolgerung: Die GI Nebenwirkungsrate nach IMRT mit täglicher Image Guidance war exzellent. GU Nebenwirkungsraten 
waren akzeptabel und standen in engem Zusammenhang den urogenitalen Beschwerden vor Radiotherapie.
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Introduction
Significantly increased gastrointestinal (GI) toxicity was the 
major drawback of three-dimensional conformal radiotherapy 
(3D-CRT)-based dose-escalation in the treatment of prostate 
cancer (PCA) [1, 4, 9, 15, 22, 31]. The development of intensi-
ty-modulated radiation therapy (IMRT) allowed better pres-
ervation of the organs at risk and significantly decreased GI 
toxicity compared to 3D-CRT [6, 18, 30]. Thus, today IMRT 
is the gold-standard treatment for radiotherapy (RT) of PCA 
[10, 28]. To account for the interfractional and intrafractional 
movement of the prostate [13, 21, 22, 29], image guidance was 
shown to be essential to avoid large safety margins around the 
clinical target volume (CTV). This report presents the pre-
treatment GI and genitourinary (GU) morbidity (PGUM) 
rates as well as acute and late GI/GU toxicity and early bio-
chemical control data of 102 patients treated using high-dose 
IMRT with daily image-guidance. 
Patients and Methods
Patient Selection and Characteristics
A total of 108 consecutive men with histologically proven 
PCA and cN0 cM0 status were treated by IMRT with daily im-
age guidance after obtaining informed consent in accordance 
with the standards of the local ethics committee. The pretreat-
ment staging included a digital rectal examination, transrectal 
ultrasound (TRUS), biopsy with specification of the Gleason 
score, prostate-specific antigen (PSA), computed tomography 
(CT) and/or magnetic resonance imaging (MRI), a total-body 
bone scan, and was defined according to the 2002 American 
Joint Committee on Cancer tumor, lymph nodes, and metas-
tasis system [27]. Risk of recurrence was assessed according to 
the National Comprehensive Cancer Network practice guide-
lines in oncology (www.nccn.org). A total of 6 patients were 
excluded from the study, 1 with a change in the treatment plan 
during the treatment, 1 because of interruption of the RT for 
3 weeks, 1 with different dose constraints than described below 
and 3 patients because of death in the absence of PCA recur-
rence < 9 months after RT (insufficient follow-up). The study 
population, thus, consisted of 102 patients, treated between 
06/2004 and 03/2008. Patients were retrospectively analyzed. 
Median age of the patients was 69 years (range, 50–81 years), 
median follow-up was 39 months (range, 16–61 months). No 
patient was lost to follow-up, 87/102 (85%) patients had a min-
imal follow-up of 24 months. The risk groups were as follows: 
low, intermediate, and high risk in 21 (21%), 28 (27%), and 
53 (52%) patients, respectively. A total of 24/102 (24%) had 
undergone a transurethral resection of the prostate (TUR-P) 
a median of 42 months prior to IMRT (range, 1–199 months). 
In 9 of these patients, the time between TUR-P and IMRT 
was < 12 months. The clinical characteristics of the patients 
are shown in Table 1. 
Hormonal Therapy
A total of 66 patients (65%) received concomitant and ei-
ther neoadjuvant or adjuvant hormonal therapy (HT), with a 
median duration of 6 months (range, 1–34 months). Indica-
tions for HT were size reduction of the prostate, or interme-
diate or high-risk features. A total of 65 patients received 
combined androgen blockade consisting of antiandrogen and 
gonadotropin-releasing hormone analogue. One patient re-
ceived antiandrogen monotherapy. 
External Beam Radiotherapy
All patients were treated with 80 Gy IMRT in standard frac-
tionation with daily image-guidance  as previously described 
[8]. Briefly, prior to the treatment, three gold markers were 
implanted into the prostate of every patient under TRUS 
Table 1. Patient characteristics. PSA: prostate-specific antigen, FU: fol-
low-up, TUR-P: transurethral resection of the prostate. aMedian time 
between TUR-P and IMRT was 42 months (range, 1–199 months), in 9 
patients the time interval was <12 months; bperiod after completion 
of treatment. 
Tabelle 1. Patientencharakteristika. PSA: Prostata-spezifisches Antigen, 
FU: follow-up, TUR-P: transurethrale Prostataresektion. aDie mediane 
Zeit zwischen TUR-P und IMRT betrug 42 Monate (1–199 Monate), bei 
9 Patienten war das Intervall <12 Monate; bZeitraum nach Abschluss 
der Behandlung. 
Total patients n = 102 (%)
Age
≤69 years 52 (51)
>69 years 50 (49)
Tumor classification
cT1 37 (36)
cT2 21 (21)
cT3a 24 (23)
cT3b 18 (18)
cT4  2 (2)
Gleason score
2–6 47 (46)
7 43 (42)
8–10 12 (12)
Pre-treatment PSA
≤10 ng/mL 55 (54)
>10 ng/mL 47 (46)
Risk group
Low 21 (21)
Intermediate 28 (27)
High 53 (52)
Hormonal therapy
no 36 (35)
yes 66 (65)
Prior TUR-Pa
no 78 (76)
yes 24 (24)
Median FU monthsb (range) 39 (16–61)
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guidance. 94 of the 102 patients (92%) underwent an MRI 
of the pelvis, and the digital data were used for image fusion 
with the planning CT. To estimate the risk for seminal vesicle 
(SV) invasion, the Roach formula [23] was calculated for each 
patient. If the risk for SV invasion was > 15%, as it was the 
case in 59 patients, the proximal third of the SV was included 
in the CTV electively. If invasion of the base of the SV was 
seen in the MRI (cT3b) image, the whole SV were electively 
included in the CTV. The planning target volume (PTV) was 
then delineated by encompassing the prostate with 5 mm 
safety margins in all directions except dorsally, where a 3 mm 
margin was added. A set of dose constraints were used and lo-
calization of the prostate prior to every RT fraction (daily im-
age-guidance) was performed as previously described [8, 29]. 
The duration of IMRT reached a median of 56 days (range, 
52–63 days). 
Follow-Up Protocol
Patients were seen by a radiation oncologist at least weekly 
during the RT. Follow-up visits were arranged 2–4 weeks af-
ter completion of IMRT and every 3–6 months for the first 
2 years and annually thereafter with a digital rectal examina-
tion and a serum PSA level obtained at each visit. Patients 
alternated follow-up visits between their urologist and radia-
tion oncologist. 
Toxicity Scoring and Biochemical Failure
Pretreatment morbidity and acute and late toxicity were 
graded using the common terminology criteria for adverse 
events (CTC AE) version 3.0 (http://ctep.cancer.gov/forms/
CTCAEv3.pdf) from the National Cancer Institute as previ-
ously described [8]. 
Biochemical no evidence of disease (bNED) was assessed 
according to the Phoenix criteria, defining a biochemical fail-
ure as a PSA rise of 2 ng/ml or more above the nadir PSA 
[24]. 
Statistical Analysis
Descriptives included absolute and relative frequencies for 
categorical variables, median and range for quantitative vari-
ables. The primary objective was the occurrence of acute and 
late ≥ grade 2 GI and GU toxicity. For statistical analysis, age 
(≤ vs. > 69 years), PTV size (≤ vs. > 94 cm3), PTVDmax (≤ 83.9 
Gy vs. > 83.9 Gy), rectal V75 (≤ 4% vs. > 4%) and rectal V47 
(≤ 17% vs. > 17%) were grouped according to the median. 
PGUM (grade 0–1 vs. grade 2–3), acute and late GI toxic-
ity (grade 0 vs. grade 1–2), and acute and late GU toxicity 
(grade 0–1 vs. grade 2–3) were grouped. Categorical variables 
were compared using Fisher’s exact test. Estimation of actu-
arial rates were calculated using the Kaplan–Meier product 
limit methodology and compared using the log-rank test 
[11]. Univariate Cox regression and a multiple Cox regres-
sion model with forward and backward selection was used to 
determine independent prognostic factors for decreased late 
≥ grade 2 GU toxicity-free survival [3]. Variables were includ-
ed in the model if the univariate p value was < 0.1. Statisti-
cal significance was considered on a 2-sided level of α = 0.05. 
Statistical analysis was performed with SPSS version 16.0 
(SPSS Inc., Chicago, IL).
Results
Acute and Late Gastrointestinal Toxicity
Acute grade 1 GI toxicity was experienced in 35 patients 
(34%), while grade 2 toxicity was observed in 2 patients (2%) 
with diarrhea being the most commonly observed symptom. 
Acute grade 3 GI toxicity was absent (Table 2).
Late grade 1 and 2 GI toxicity occurred in 31 (30%) and 5 
(5%) patients, respectively, and rectal bleeding was the most 
commonly observed symptom. Late grade 3 GI toxicity was 
absent. No patient reported experiencing fecal incontinence. 
The median time from the completion of IMRT to the oc-
currence of late ≥ grade 2 GI toxicity was 25 months (range, 
12–41 months). The actuarial likelihood at 5 years for the de-
velopment of late ≥ grade 2 GI toxicity was 7%. The incidence 
of late GI toxicity decreased as time from treatment elapsed. 
At the last follow-up visit, late grade 1 toxicity was present in 
19 (19%) patients, and no patient suffered of late grade 2 GI 
Table 2. Pre-treatment gastrointestinal morbidity and gastrointesti-
nal acute and late toxicity. Pre-Tx: pre-treatment; athe highest toxicity 
in a patient was counted as a single event; b during therapy and until 3 
months after completion; c maximal late toxicity >3 months after com-
pletion of therapy; d incidence of late toxicity at last follow-up visit. 
There was no grade ≥ grade 3 GI toxicity observed. 
Tabelle 2. Gastrointestinale Morbidität vor Behandlung und akut und 
spät gastrointestinale Nebenwirkungen. Pre-Tx: vor Behandlung;. 
adie maximal erreichte Toxizitäts eines Patienten wurde als 1 Ereignis 
gewertet; bwährend und bis 3 Monate nach Abschluss der Behandlung; 
c maximale Spättoxizität >3 Monate nach Abschluss der Behandlung; 
dInzidenz von Spättoxizität beim letzten Nachuntersuchungstermin 
(≥ Grad-3-GI Toxizität wurde nicht beobachtet).
Pre-Tx Acuteb Latec Last lated
Toxicity Grade n (%) n (%) n (%) n (%)
Diarrhea 0 102 (100) 75 (74) 95 (93) 102 (100)
1  0 25 (24)  7 (7)  0
2  0  2 (2)  0  0
Rectal pain 0 101 (99) 94 (87) 98 (96) 100 (98)
1  1 (1)  8 (13)  2 (2)  2 (2)
2  0  0  2 (2)  0
Rectal bleeding 0  99 (97) 95 (93) 73 (72)  85 (83)
1  3 (3)  7 (7) 26 (25)  17 (17)
2  0  0  3 (3)  0
Highest GIa 0  99 (97) 65 (64) 66 (65)  83 (81)
1  3 (3) 35 (34) 31 (30)  19 (19)
2  0  2 (2)  5 (5)  0
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toxicity anymore at that time. Acute and late GI toxicity was 
not associated with any DVH parameter tested.
Acute and Late Genitourinary Toxicity
Prior to treatment, 15 patients (15%) had grade 2 and 2 pa-
tients (2%) suffered of grade 3 PGUM (Table 3). The most 
commonly observed PGUM symptoms were increased fre-
quency/urgency and retention. PGUM was not associated 
with a history of prior TUR-P (p = 1.0). After treatment acute 
grade 2 and 3 GU toxicity occurred in 44 (43%) and 5 (5%) 
patients, respectively. Acute ≥ grade 2 GU toxicity was sig-
nificantly more common in patients who already suffered of 
PGUM (p < 0.001). Interestingly, acute toxicity was decreased 
in patients with history of TUR-P (n = 24, p = 0.039); how-
ever, if only patients with TUR-P < 12 months prior to IMRT 
were analyzed (n = 9), acute GU toxicity was not significantly 
different (p = 0.50). Acute GU symptoms were often amelio-
rated with α-blockers or anti-inflammatory medications. Late 
grade 2 and 3 GU toxicity occurred in 21 (21%) and 1 (1%) 
of patients, respectively. There was no acute or late grade 4 
GU toxicity. The median time from the completion of IMRT 
to the occurrence of late ≥ grade 2 GU toxicity was 34 months 
(range, 4–61 months). The actuarial incidence of late ≥ grade 
2 GU toxicity was 27% at 5 years. Late ≥ grade 2 GU toxicity-
free survival was significantly associated with the presence of 
PGUM (p < 0.001) (Figure 1), presence of TUR-P < 12 months 
prior to IMRT (p = 0.003), presence of acute GU toxicity (p = 
0.01), older age (p = 0.03) but not with HT (p = 0.66), PTV size 
(p = 0.76), or PTV Dmax (p = 0.2). After multiple Cox regression 
analysis with forward and backward selection, PGUM was an 
independent positive predictor of late ≥ grade 2 GU toxicity-
free survival (hazard ratio = 9.4 (95% confidence interval: 4.1, 
22.0), p < 0.001) (Table 4). When all patients with a history of 
TUR-P were analyzed (n = 24), late ≥ grade 2 GU toxicity-free 
survival was not significantly decreased (p = 0.32). Interesting-
ly, late GU toxicity decreased as time from treatment elapsed. 
At last follow-up visit, only 7 (7%) or 1 (1%) still complained 
of late grade 2 or 3 GU toxicity, respectively, being less than 
Table 3. Pre-treatment genitourinary morbidity and genitourinary 
acute and late toxicity. Pre-Tx: pre-treatment; athe highest toxicity 
in a patient was counted as a single event; bduring therapy and until 
3 months after completion; c maximal late toxicity >3 months after 
completion of therapy; dincidence of late toxicity at last follow-up 
 visit. There was no grade ≥ grade 4 GU toxicity observed. 
Tabelle 3. Urogenitale Morbidität vor Behandlung und akut und spät 
urogenitale Nebenwirkungen. Pre-Tx: vor Behandlung; adie maximal 
erreichte Toxizitäts eines Patienten wurde als 1 Ereignis gewertet; 
bwährend und bis 3 Monate nach Abschluss der Behandlung; cmaxi-
male Spättoxizität >3 Monate nach Abschluss der Behandlung; dIn-
zidenz von Spättoxizität beim letzten Nachuntersuchungstermin 
(≥ Grad-4-GU Toxizität wurde nicht beobachtet). 
Pre-Tx Acuteb Latec Last lated
Toxicity Grade n (%) n (%) n (%) n (%)
Dysuria 0 95 (93) 63 (62) 93 (91) 98 (96)
1 7 (7) 30 (30) 8 (8) 4 (4)
2 0 7 (7) 1 (1) 0
3 0 2 (2) 0 0
Incontinence 0 94 (92) 92 (90) 88 (86) 92 (90)
1 7 (7) 9 (9) 12 (12) 9 (9)
2 1 (1) 1 (1) 2 (2) 1 (1)
Retention 0 57 (56) 52 (51) 71 (70) 91 (89)
1 38 (37) 25 (25) 25 (24) 10 (10)
2 6 (6) 23 (22) 5 (5) 0
3 1 (1) 2 (2) 1 (1) 1 (1)
Frequency/ur-
gency
0 65 (64) 23 (23) 51 (50) 71 (70)
1 28 (27) 46 (45) 34 (33) 24 (23)
2 8 (8) 30 (29) 17 (17) 7 (7)
3 1 (1) 3 (3) 0 0
Hematuria 0 102 (100) 102 (100) 93 (91) 99 (97)
1 0 0 7 (7) 3 (3)
2 0 0 2 (2) 0
Highest GUa 0 39 (38) 11 (11) 37 (36) 59 (58)
1 46 (45) 42 (41) 43 (42) 35 (34)
2 15 (15) 44 (43) 21 (21) 7 (7)
3 2 (2) 5 (5) 1 (1) 1 (1)
1,0
0,8
0,6
0,4
0,2
0,0
0 20 40 60
Time (months)
p < 0.001
without pre-treatment GU mobidity (PGUM)
with pre-treatment GU morbidity (PGUM)
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Figure 1. Actuarial analysis of 3-year late ≥ grade 2 GU toxicity-free sur-
vival stratified by the presence of pretreatment genitourinary morbid-
ity (PGUM).
Abbildung 1. Kaplan-Meier-Analyse des spät (≥ Grad 2) urogenital 
nebenwirkungsfreien Überlebens nach 3 Jahren, stratifiziert nach 
Vorhandensein von urogenitaler Morbidität vor Behandlung (PGUM).
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half of the patients who suffered of grade 2 or 3 PGUM prior 
to treatment.
Biochemical Control
With a median follow-up of 39 months, it is too early to re-
port sound biochemical control rates, especially taking into 
account that 65% of the patients underwent HT. However, 
after IMRT, 92% (61/66) of patients with and 50% (18/36) of 
patients without HT reached a PSA nadir value ≤ 0.5 ng/mL. 
During follow-up, 12 patients (12%) experienced biochemical 
relapse, all of whom belonged to the high-risk of recurrence 
group. The actuarial 5-year biochemical relapse-free survival 
was 100%, 100%, and 68% for low-, intermediate- and high-
risk patients, respectively (p = 0.003). 
Discussion
Radical prostatectomy combined with pelvic lymphadenecto-
my is known to produce comparable tumor control rates com-
pared to conventional dose 3D-CRT in localized PCA [5, 16], 
and introduction of nerve-sparing operation technique could 
significantly reduce the risk of associated severe stress inconti-
nence [14]. Thus, modern RT is required to achieve low toxic-
ity rates and high long-term effectiveness to be recommended 
as a therapeutic alternative to radical prostatectomy. 
After a median follow-up of 39 months, our results after 
high-dose IMRT daily image-guidance are encouraging with 
respect to observed treatment-related toxicity. Acute and late 
grade 3 GI toxicity was absent, while acute and late grade 2 GI 
toxicity was observed in 2% and 5% of the patients, respective-
ly. 
Concerning GU toxicity, notably, our patients suffered of 
a significant PGUM, being of grade 2 and 3 in 15% and 2%, 
respectively, of the patients prior to IMRT. Acute grade 2 and 
3 GU toxicity occurred in 43% and 5% and late grade 2 and 3 
GU toxicity was observed in 21% and 1%, respectively. 
Our acute toxicity rates compare favorably with those 
reported for 111 patients treated with IMRT 78 Gy within a 
prospective randomized trial, where the acute grade 2 and 3 
GI toxicity was 41% and 8% and the acute grade 2 and 3 GU 
toxicity was 21% and 2% (CTC score), respectively [19]. 
Others have reported the toxicity profile (CTC score) 
after ultrahigh-dose IMRT with 86.4 Gy after a median fol-
low-up of 53 months and acute grade 2 GI toxicity was 8%, 
acute grade 2 and 3 GU 22% and 1%, respectively, actuarial 
late ≥ grade 2 GI toxicity at 5 years was 4% and actuarial late 
≥ grade 2 GU toxicity was 16% at 5 years [2]. Compared to this 
study, our GI rates seem comparably low; however, GU toxic-
ity rates were higher in our patients despite the use of a lower 
total dose in our patients (80 Gy vs. 86.4 Gy). Importantly, one 
has to consider that in our treatment plans the dose coverage 
of the PTV was defined more strictly, thus, aiming to set the 
V95 to > 99% (volume of the PTV receiving at least 95% of the 
prescribed dose > 99%) [8]; however, the treatment plan cri-
teria for 81 Gy or 86.4 Gy plans were V95 > 90% or V95 > 85%, 
respectively [18], moreover for 81 Gy and 86.4 Gy, a lower 
single fraction dose (1.8 Gy) was used. 
In this study, a significant association between acute GI/
GU toxicity and decreased late GI/GU toxicity-free survival 
could be demonstrated. This is in accordance with the findings 
of others [12, 26, 30]. In addition, we could also describe not 
only the PGUM rate of our patients and its significant associa-
tion with acute GU toxicity, but also its role as an independent 
positive predictor for decreased late GU toxicity-free survival. 
A relative large proportion of our patients (24%) had under-
gone TUR-P at different times prior to IMRT. We found that 
a history of TUR-P < 12 months before IMRT was associated 
with decreased late ≥ grade 2 GU toxicity-free survival. An as-
sociation between previous TUR-P and GU toxicity has been 
previously described [20].
In our patients, HT did not influence the incidence of late 
GI or GU toxicity. A large meta-analysis [17] recently demon-
strated that addition of short-term HT significantly decreased 
GI and GU late toxicities. 
Late toxicity after RT is known to increase over time. 
However, during follow-up of our series of patients, the in-
cidence of late GI and especially of late GU toxicity were 
decreasing. At the last follow-up visit, late GU toxicity rates 
dropped below half of the observed PGUM rates. A similar re-
port was recently made by others [7], who showed that patients 
presenting with obstructive urinary symptoms experienced a 
clear symptom relieve after IMRT ± HT. Generally, the grade 
2 GU toxicities observed in our patients consisted of increased 
Table 4. Univariate and multiple Cox regression analysis of factors 
associated with late ≥ grade 2 genitourinary toxicity-free survival. 
RR: relative risk, CI: 95% RR confidence intervals, TUR-P: transurethral 
resection of the prostate, IMRT: intensity modulated radiation therapy, 
PGUM: pre-treatment genitourinary morbidity. 
Tabelle 4. Univariate und multiple Cox Regressionsanalyse von Fak-
toren welche mit spät-≥Grad-2-urogenital nebenwirkungsfreiem 
Überleben assoziiert sind. RR: relatives Risiko, CI: 95% RR Konfidenzin-
tervalle, TUR-P: transurethrale Prostataresektion, IMRT: Intensitäts-
modulierte Radiotherapie, PGUM: urogenitale Morbidität vor Behand-
lungsbeginn.
Factor RR CI p
Univariate Cox regression:
PTV size > 94 cm3 vs. ≤ 94 cm3 1.1 0.5–2.6 0.763
PTV Dmax > 83.9 Gy vs. ≤ 83.9 Gy 1.7 0.7–4.1 0.208
Age > 69 years vs. ≤ 69 years 2.5 1.0–6.2 0.042
TUR-P <12 months prior to IMRT 4.0 1.5–11.2 0.007
Acute grade 2–3 toxicity versus 
grade 0–1
3.0 1.2–7.8 0.020
PGUM grade 2–3 vs. grade 0–1 9.4 4.1–22.0 <0.001
Multiple Cox regression:
PGUM grade 2–3 vs. grade 0–1 9.4 4.1–22.0 <0.001
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frequency/urgency or retention and were often significantly 
improved after α-blocker or anti-inflammatory medications. 
These drugs were received by most of the symptomatic pa-
tients during IMRT and during follow-up; thus, this drug 
therapy at least contributed to the observed decrease of late 
GU toxicity during time. 
The follow-up of less than 5 years is too short to provide 
sound biochemical control data. However, all observed events 
of biochemical relapse (12%) occurred in patients with high-
risk features and our actuarial 5-year biochemical relapse-
free survival rates of 100%, 100%, and 68% are comparable 
with the 5-year rates of 98%, 85%, and 70% described after 
ultrahigh-dose IMRT for low-, intermediate-, and high-risk 
patients, respectively [2].
We are aware of the obvious limitations of our study, be-
ing the retrospective nature of the study and limited follow-
up. Nevertheless, this report provides strong evidence for the 
low toxicity profile of high-dose IMRT. In the decision mak-
ing for appropriate local treatment of PCA, the patient should 
not be informed about “RT” but should be informed about 
“modern RT” and its associated low treatment-related acute 
and late toxicity.
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